Executive Insight

Building the Next Phase of Biologicals on Performance, Not Projection

By Giuseppe Natale, Vedalia

The biologicals space stands at a critical crossroads.

Over the past decade, biological solutions have moved from niche innovation to strategic priority. Farmers are actively seeking sustainable tools to improve soil health, manage resistance, and comply with increasingly demanding regulatory frameworks. The field-level interest is real. The need is real. The agronomic rationale is strong.

Yet, behind this promising landscape, a more uncomfortable truth is emerging.

While demand for biologicals has grown steadily, valuations in the sector have often grown exponentially — detached from operational fundamentals. Capital flowed generously. Financial investors entered aggressively. “Buy-and-build” became the dominant strategy. Growth narratives were compelling. The future looked brilliant on pitch decks.

Today, many of those narratives are being stress-tested by reality.

Shared Accountability: The Role of Leadership

It would be too simple to attribute the current tension exclusively to financial investors. Founders and management teams have also played a role in shaping expectations. In the race to attract capital, some companies embraced valuations that exceeded operational maturity. Optimistic projections were sometimes presented as near certainties. Technical potential was occasionally communicated as commercial readiness. Early-stage validation was framed as scalable proof.

In certain cases, leadership teams underestimated the complexity ahead. In others, ambition overtook prudence. The pressure to demonstrate hyper-growth can distort incentives. When valuation becomes the primary benchmark of success, discipline weakens. Expansion accelerated, and acquisitions justified prematurely. Integration is postponed with commercial readiness assumed.

Transparency, realistic forecasting, and operational humility are as essential as capital.

The Illusion of Synergy

The buy-and-build model promised scale, integration, and cross-selling advantages. In theory, assembling complementary biological platforms under one umbrella would create efficiency and market power.

In practice, many acquisitions remained exactly what they were at the start: separate entities sharing a logo. Different technologies. Different cultures. Different manufacturing processes. Different commercial strategies.

Without deep integration, synergies remain theoretical. What should have become a cohesive platform instead resembles a patchwork portfolio — complex to manage, expensive to coordinate, and difficult to position clearly in the market. Scale without integration is not strength. It is overhead.

The Underestimated Go-To-Market Challenge

Agriculture is not software. Biological products require:

• Technical education
• Field validation across geographies
• Strong local agronomic support
• Consistency of performance under variable conditions

Many business plans underestimated the time, capital, and patience required to build farmer trust. Adoption cycles are long. Distribution networks are conservative. Demonstrating reliability across seasons is non-negotiable. Spreadsheets assumed acceleration. Reality demanded repetition.

When Finance Leads the Business

Perhaps the most structural issue is philosophical. In several cases, financial engineering came before agronomic validation. Investment theses were built around market size projections, not around proven problem-solving capability. Expansion strategies were designed in boardrooms rather than in fields.

But agriculture has a simple rule: if the product does not consistently solve a farmer’s problem, nothing else matters. Not branding. Not storytelling. Not capital structure. The biologicals sector does not need more financial creativity. It needs disciplined execution — from investors, from founders, and from managers alike.

The best vaccine for any investment in biologicals is simple: start from the product. Does it solve a concrete agronomic problem? Does it generate measurable value for farmers? Is adoption based on repeat purchase, not promotional push? Business fundamentals must lead. Finance must support — not the other way around.

A Maturing Industry

What we may be entering is not a collapse, but maturation. Hype cycles are natural in emerging sectors. Correction phases are equally natural. They separate narrative-driven growth from substance-driven growth.

Biologicals remain one of the most important frontiers in agriculture. But the next chapter will likely reward operational discipline over financial optimism — and leadership grounded in realism rather than projection.

The reality check is not a threat. It is an opportunity. An opportunity to rebuild valuations on performance. To prioritize integration over acquisition. To design strategies from agronomy upward. To restore credibility where it may have been stretched. And above all, remember that in agriculture, value is created in the field — not in an Excel model.

These observations are not meant to offend or judge, but to encourage discipline and responsibility. It is simply my conviction that investors and entrepreneurs alike must act with prudence — because the future of our industry, and of agriculture itself, depends on our ability to combine bold vision with grounded execution: feet on the ground, heads in the clouds.

BioAgTech World Congress & Expo 2026

Advancing agriculture through grounded innovation and operational excellence.